EQL Pharma AB (FRA:7JK) Retained Earnings : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. EQL Pharma AB's retained earnings for the quarter that ended in Mar. 2024 was €0.00 Mil.

EQL Pharma AB's annual retained earnings increased from Mar. 2022 (€5.25 Mil) to Mar. 2023 (€7.69 Mil) but then declined from Mar. 2023 (€7.69 Mil) to Mar. 2024 (€0.00 Mil).

EQL Pharma AB Retained Earnings Historical Data

The historical data trend for EQL Pharma AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Retained Earnings Chart

EQL Pharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Retained Earnings

Get a 7-Day Free Trial

2.34

5.25

7.69

EQL Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															7.69	-	-	-	-

EQL Pharma AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

EQL Pharma AB (FRA:7JK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

EQL Pharma AB (FRA:7JK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

EQL:Sweden

Address

Stortorget 1, 3rd Floor, Lund, SWE, 222 23

Website

http://www.eqlpharma.com

EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines